Prestige Biologics Co., Ltd.

KOSDAQ:A334970 Stock Report

Market Cap: ₩396.4b

Prestige Biologics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of A334970?
Owner TypeNumber of SharesOwnership Percentage
Institutions13,7370.0177%
Private Companies3,248,5844.2%
Individual Insiders15,708,62520.3%
General Public27,323,96335.3%
Public Companies31,122,72840.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.4%.

Top Shareholders

Top 11 shareholders own 64.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
40.2%
Prestige BioPharma Limited
31,122,728₩159.3b105%no data
10.1%
So-Yeon Park
7,807,821₩40.0b0%no data
9.96%
Jinwoo Kim
7,711,601₩39.5b0%no data
4.2%
Octava Fund Limited
3,248,584₩16.6b0%no data
0.1%
Hyuncheol Dong
80,000₩409.6m0%no data
0.058%
Jae-Yeong Yang
45,000₩230.4m0%no data
0.036%
Deok-hun Hyeon
27,962₩143.2m0%no data
0.024%
Youngsu Lim
18,449₩94.5m0%no data
0.02%
Lai Way Tay
15,792₩80.9m0%no data
0.018%
State Street Global Advisors, Inc.
13,737₩70.3m-0.99%no data
0.0026%
Seok-jae Seo
2,000₩10.2m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 15:45
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prestige Biologics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution